TYRUKO

NDC 61314-543 · Sandoz Inc

Generic namenatalizumab-sztn

Dosage formINJECTION

RouteINTRAVENOUS

Active ingredient(s)NATALIZUMAB

Strength300 mg/15mL

Pharmacologic classIntegrin Receptor Antagonist [EPC], Integrin Receptor Antagonists [MoA]

Marketing categoryBLA

Packages

61314-543-94 — 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-543-94) / 15 mL in 1 VIAL, SINGLE-DOSE

Q5134 — Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg Medicare Part B payment limit (ASP + 6%): $24.49

FDA lists these products with the same active ingredient.

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.